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Summary
Background: Over recent decades, a resurgence of invasive group A streptococcal (GAS) infec-
tions has been observed; GAS remains a rare cause of pyogenic meningitis. We report herein
population-based findings of long-term surveillance for GAS meningitis in Salvador, Brazil, and
estimate the overall burden of invasive GAS infections.
Methods: From February 1996 to February 2007 we conducted active surveillance for GAS
meningitis in the state reference hospital for infectious diseases in Salvador, Brazil. Data on
clinical presentation, laboratory records, and outcome were collected through interviews and
chart review. GAS isolates were evaluated for antimicrobial susceptibility and emm type.
Results: We identified 20 cases of GAS meningitis, which accounted for 0.9% of all culture-proven
bacterial meningitis in the study period. The mean annual incidence of GAS meningitis was 0.03
cases per 100 000 population inmetropolitan Salvador and peaked in children<1 year of age (0.67
cases per 100 000 population). Among 17 cases with clinical information available, 41% required
intensive care unit support and 25% died. Tested isolates were susceptible to penicillin and
exhibited large emm type diversity. Based on the incidence of GAS meningitis, we estimate that
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the annual incidence of GAS infection is 3 cases per 100 000 population in metropolitan Salvador.
Conclusions: Although rare, GAS is a life-threatening cause of bacterial meningitis. Knowledge of
the incidence and emm type variability of the disease is necessary for planning immunization
strategies.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Streptococcus pyogenes, also known as group A Streptococ-
cus (GAS), is one of the most common human pathogens and
causes a wide spectrum of disease, including invasive and
non-invasive infections, as well as non-suppurative compli-
cations.1,2 In the late 1980 s, global attention to GAS
increased because of reports of severe invasive GAS infec-
tions.3—5 Recently, Carapetis et al. reviewed population-
based data to estimate the worldwide burden of GAS dis-
eases. They found an unexpectedly high figure of over
660 000 cases of invasive GAS infections and 163 000 deaths
each year.6 Although epidemiological studies from Europe
and the USA have shown a sustained, high incidence of severe
invasive streptococcal infections,7,8 there are scarce data on
the burden of invasive GAS infections in developing coun-
tries, where the burden is expected to be higher.6
Meningitis is an uncommon presentation for GAS invasive
disease, accounting for only 1% of all GAS systemic infec-
tions.7—9 Conversely, GAS is an uncommon source of menin-
gitis; less than 1% of all bacterial meningitis is due to
GAS.10,11 Most articles about GAS meningitis are case reports
with clinical descriptions of disease. There is little popula-
tion-based data on the frequency and severity of the invasive
GAS disease in less developed countries.
We report herein the epidemiology and clinical char-
acteristics of GAS meningitis cases prospectively identified
during 11 years of population-based surveillance for bac-
terial meningitis in Salvador, Brazil. We used GAS menin-
gitis incidence data to estimate the overall burden of
invasive GAS infections in the region. In addition, we
evaluated the microbiologic features of the isolates to
determine their emm type (M-protein gene) distribution
and penicillin susceptibility.
Materials and methods
Surveillance
In 1996, we established hospital-based surveillance for bac-
terial meningitis at Hospital Couto Maia, the state infectious
disease reference hospital, in Salvador, Brazil. State health
procedures require that all suspected cases of meningitis in
the region be referred to this hospital for diagnostic proce-
dures, including routine lumbar puncture, cerebrospinal
fluid (CSF) examination, and isolation precaution as indi-
cated. Notification of bacterial meningitis cases to health
officials is mandatory in Brazil, and the study hospital
reports 95% of the cases among residents of metropolitan
Salvador. From February 10, 1996, to February 9, 2007, the
study team actively reviewed laboratory records 5 days a
week to identify new culture isolates from patients with
suspected meningitis.Case definition and data collection
A case of culture-proven bacterial meningitis was defined as a
patient who had: (1) clinical presentation of meningitis,
characterized by fever, neck stiffness, and altered mental
status, (2) abnormal CSF examination, and (3) positive CSF or
blood culture. A case of culture-proven GAS meningitis was
defined as above, with the addition of culture isolation of S.
pyogenes. The study team of physicians and medical students
conducted interviews and medical record reviews, using a
standardized data entry form to collect information on
demographics, clinical presentation, and outcome charac-
teristics. Patients were enrolled in the study according to
informed consent procedures approved by the institutional
review boards of the Oswaldo Cruz Foundation, Brazilian
Ministry of Health, and the New York-Presbyterian Hospital,
New York, USA.
Laboratory analysis
GAS isolates were identified on the basis of standard
methods, which included colony morphology, hemolytic
activity on blood agar medium, Gram staining character-
istics, catalase reaction, and susceptibility to bacitracin.
We used Lancefield group A-specific antiserum (Avipath-
Strep, Omega Diagnostics, UK) to confirm the isolate ser-
ogroup. Penicillin susceptibility was tested using the broth
microdilution method as recommended by the Clinical and
Laboratory Standards Institute (CLSI).12 Emm typing was
performed on the basis of sequencing of the variable M
serotype-specific region of the emm gene amplicon as
described by the Centers for Disease Control and Preven-
tion (CDC) protocol.13 The type was assigned using the
emm type database at CDC14 and GenBank (http://
www.ncbi.nlm.nih.gov/BLAST/).
Statistical analysis
Epi Info version 3.2 software (CDC, Atlanta, GA, USA) was
used for data entry and statistical analysis. Categorical and
continuous variables are presented as number and propor-
tion, and median and range, respectively. We estimated the
mean annual cumulative incidence for GAS meningitis for
cases with residence in metropolitan Salvador, a region
comprised of Salvador and 10 surrounding municipalities
(population 3 021 572). Based on the incidence of GASmenin-
gitis for metropolitan Salvador and on recent population-
based studies from Europe, the USA, and Canada showing that
meningitis corresponds to 1% of all cases of invasive GAS
disease,7—9 we estimated the overall burden of invasive GAS
infections for metropolitan Salvador. Incidences were calcu-
lated using population data from the 2000 Brazilian National
Census.15
Table 1 Clinical characteristics of group A streptococcal
meningitis cases identified during surveillance; Salvador,
Brazil.
Characteristic No. of cases (%) or
median (IQR) (N = 17)a
Symptoms and signs
Days of symptoms 3 (2—5)
Fever 16 (94)
Vomiting 13 (76)
Neck stiffness 12 (71)
Headacheb 7 (64)
Seizures 10 (59)
Altered mental status c 10 (59)
Focal neurological deficit d 3 (18)
Outcome
ICU hospitalization 7 (41)
Deathe 4 (25)
Length of hospitalization,
in dayse
For survivals 17 (14—22)
For deaths 7 (4—9)
IQR, interquartile range; ICU, intensive care unit.
a Data on symptoms and outcomewere available for 17 of the 20
cases, except when noted.
b Data on headache were available for 11 cases.
c Altered mental status was defined by inability to follow
commands, lethargy, torpor, or coma.
d Focal neurological deficit included nystagmus, mydriasis, and
ptosis.
e Data on death and length of hospitalization were available for
16 cases because one patient was transferred and final outcome
was unknown.
Figure 1 Mean annual cumulative incidence of group A strep-
tococcal meningitis for metropolitan Salvador, 1996—2006.
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Burden of GAS infections
During the 11-year study period, the surveillance hospital
consecutively identified 2255 cases of culture-positive bac-
terial meningitis, of which 20 (0.9%) were identified as GAS
meningitis. Based on the nine (45% of 20) cases that resided in
metropolitan Salvador, the mean annual incidence of GAS
meningitis was 0.03 cases per 100 000 population. Children
<1 year old had the highest incidence (0.67 cases per 100 000
population), which markedly decreased with age (Figure 1).
The incidence for age groups <5, <19, and 20 years of age
were 0.17, 0.05, and 0.01 cases per 100 000 population,
respectively. Meningitis is believed to account for 1% of all
invasive GAS infections.7—9 Based on this ratio and the
observed incidence of GAS meningitis in Salvador, we esti-
mate that the annual incidence of GAS infection is 3 cases per
100 000 population.
Case characteristics and outcome
Overall, GAS meningitis patients had a median age of 4.5
years (range 19 days—52 years). Of note, eight (40%) cases
occurred in children <1 year old and two (10%) in newborns
<1month of age. Males accounted for 11 (55%) cases. Data on
clinical presentation and outcome were available for 17 of
the 20 cases. The median length of symptoms before hospi-
talization was 3 days. The majority of cases presented with
fever, vomiting, headache, and seizures; the most frequent
findings on clinical exam were neck stiffness and altered
mental status (Table 1). We were able to identify a presump-
tive source of infection for 10 cases (59% of 17), which
included otitis media (four cases), rhinopharyngitis (three
cases), and ventriculoperitoneal shunt, meningomyelocele,
and mild cranial trauma (one case each) (Table 2).
All 17 cases received penicillin or ceftriaxone as the initial
antibiotic therapy, and eight (47%) cases also received ster-
oids on the first day of treatment. Intensive care unit (ICU)admission was indicated for seven (41%) cases. Despite ICU
care, four (25% of 16) patients died. Outcome was unknown
for one of the 17 patients, who was transferred to another
hospital. Although age was not significantly associated with a
poor outcome, all deaths occurred in patients <15 years of
age (Table 2).
Laboratory analysis
All 20 cases of GASmeningitis had positive CSF cultures, while
two (18%) had positive blood cultures among the 11 patients
from whom cultures were obtained. Complete data on the
CSF findings were available for 19 of the 20 cases. Themedian
CSF white cell count was 2.4  109 cells/l (interquartile
range (IQR): 0.65  9  109cells/l), median glucose was
20 mg/dl (IQR: 2022 mg/dl), and median protein was
400 mg/dl (IQR: 250500 mg/dl).
We examined penicillin susceptibility for 17 GAS strains
isolated from cases with clinical information available. All
tested isolates were fully susceptible to penicillin; the mini-
mum inhibitory concentration ranged from <0.016 mg/ml to
0.062 mg/ml. emm typing of the 20 isolates found 17 differ-
ent emm type sequences. emm types 25 and 73 were found in
more than one isolate [3 of 20 (15%) and 2 of 20 (10%)],
respectively) (Table 2). Among the 20 isolates, two had emm
types (11 and 92) that are represented in the 26-valent GAS
vaccine.
Table 2 Characteristics of group A streptococcal meningitis cases and isolates identified during surveillance; Salvador, Brazil.
Case Month/year of diagnosis Age Sex Presumptive infection source Isolate emm type Outcome
1 05/1996 5 years F Otitis media 25 Discharged
2 05/1996 6 years M None 85 Died
3 08/1996 5 months M Mild cranial trauma 123 Discharged
4 09/1996 6 months M Ventriculoperitoneal shunt 25 Discharged
5 04/1998 4 years M Rhinopharyngitis 25 Discharged
6 05/1998 31 years F NA 98 NA
7 02/1999 17 years F Otitis media 112 Discharged
8 07/2000 52 years M Otitis media 88 Discharged
9 11/2000 8 years M None 55 Discharged
10 09/2001 19 days F Meningomyelocele 73 Discharged
11 04/2002 2 months M None 73 Discharged
12 07/2002 23 days M None 39.1 Discharged
13 10/2002 8 years F NA 86.1 NA
14 11/2002 4 years M None 95 Died
15 09/2003 40 years F Otitis media 53 Discharged
16 11/2003 7 months F Rhinopharyngitis 81 Discharged
17 05/2004 45 years M NA 44/61.0 NA
18 10/2004 1 month F None 92 Transferred
19 04/2006 4 months M Rhinopharyngitis 11 Died
20 12/2006 13 years F None 118 Died
F, female; M, male; NA, not available.
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This series of 20 cases of GAS meningitis in Salvador, Brazil is
the largest reported from a developing country. GAS menin-
gitis corresponded to 0.9% of all cases of culture-proven
bacterial meningitis, consistent with previous reports of
0.2% to 1% of cases.10,11
The overall incidence of GAS meningitis was similar to the
incidence of 0.04 cases per 100 000 population found in the
Netherlands between 1987 and 2000.11 The Dutch incidence
was 0.06 cases per 100 000 in children and 0.03 cases per
100 000 in adults, similar to ours results, although we found
that children<1 year of age had a risk (0.67 cases per 100 000
population) 15 times greater than that for the rest of the
population. The identification of this high-risk age group may
have implications for future GAS immunization programs.
A review estimated the annual incidence of invasive GAS
infections to range from 2.45 cases per 100 000 population in
more developed countries to 13.00 cases per 100 000 popula-
tion in less developed countries.6 Although Brazil is consid-
ered a middle-income country, the estimated burden of GAS
invasive disease of 3 per 100 000 for Salvador is closer to that
described for developed countries. This may be due to
inaccuracy in our estimation. However, the basis for the
estimate for less developed countries was a single popula-
tion-based study in Kenya; this prediction, therefore, may
not be valid for Brazil, since health statistics in Brazil differ
from those of Kenya.16,17 Moreover, as the incidence of GAS
meningitis for metropolitan Salvador was similar to that of
the Netherlands, we believe that our estimate of the burden
of invasive GAS in Salvador is reliable.
Although many reports have suggested that GAS meningi-
tis usually occurs in association with a recognized infection
focus, most commonly upper respiratory tract infections,
the absence of a predisposing condition has also beenreported.18—23 In our study, 59% of the GAS meningitis cases
were preceded by a predisposing factor, most commonly
otitis media or rhinopharyngitis. Since GAS infections of
the upper respiratory tract are among the most common
non-invasive presentations of GAS diseases and GAS menin-
gitis is a rare disease, it would be of interest to study the
mechanisms that lead from GAS invasion of the upper respira-
tory mucosa to the pathogenesis of central nervous system
infections.
Case-fatality data for GAS meningitis are somewhat con-
troversial. Literature reviews of well-documented cases of
GAS meningitis, including all age groups, have estimated a
case-fatality rate ranging from 4% to 12%.19,22,23 However,
literature reviews are limited by publication bias and com-
binations of cases from heterogeneous settings where man-
agement differences may influence outcome. In 2002, van de
Beek et al. reported the largest case series of GAS meningitis
in adults.11 Using the database of the Netherlands Reference
Laboratory for Bacterial Meningitis to identify GAS meningitis
cases, they found a case-fatality rate of 27%, similar to our
data, but at least twice that found in other review arti-
cles.19,22,23 This cannot be explained by antimicrobial resis-
tance. All 17 cases with available clinical information were
treated with a b-lactam antimicrobial agent or a third gen-
eration cephalosporin and as anticipated, all strains were
susceptible to these agents. Since both the study by van de
Beek et al. and our investigation used surveillance systems to
identify cases of GAS meningitis among defined populations,
we believe that the actual case-fatality rate associated with
GAS meningitis may be higher than previously thought.
A comparative study of non-invasive GAS isolates from
Belgium and Brazilian children conducted in 2004 found that
20 distinct emm types were identified among 200 Belgian
isolates, whereas a significantly larger diversity of emm types
(48 among 128 strains) were found in Brazil. Furthermore,
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Belgian children than from Brazilian children.24 emm types 1
and 3, which have previously been associated with severe
invasive infections,25,26 were not found in isolates from
meningitis cases in this study; the emm types varied widely.
Prior studies of invasive GAS isolates have also detected a
large diversity of emm types in different regions.27—29 In this
study the most prevalent emm type identified was emm type
25 (18%), which has been described associated with invasive
infection in Spain, the UK, and Thailand.30—32 Together these
findings suggest that, as proposed by Rogers et al.,33 the
isolation of a particular emm type among invasive isolates
may simply indicate widespread transmission of these strains
in the population, rather than a particular ability to cause
disease.
Our study has potential limitations. First, we may have
underestimated the true incidence of GAS meningitis
because antibiotic use prior to hospitalization may have
led to reduced isolation rates. Second, active surveillance
was performed in only one hospital for an extended period,
so changes in case ascertainment could have affected
incidence estimation. However, state and local protocols
for the referral of suspected meningitis cases to the study
hospital did not change during the study period. Although
clinical information and outcome were missing for three
cases, we had complete information on demographics and
city of residence for all 20 cases. Since the study was
performed in a single region our findings may not be
generalizable to other settings. However, a large propor-
tion of the population in Brazil lives in climatic and socio-
economic conditions similar to those in Salvador. The study
incidence estimates may also be applicable to other coun-
tries with a demographic and socio-economic profile simi-
lar to Brazil.
The availability of a multivalent, M protein-based vaccine
against GAS prompted this attempt to define population-
based data on the burden of GAS invasive disease and on
the distribution of emm types. We used the incidence of GAS
meningitis to estimate the overall burden of invasive GAS
infections, as population-based surveillance for bacterial
meningitis is simpler than for other GAS invasive diseases.
As several developing countries have received support from
the World Health Organization and the Global Alliance for
Vaccines and Immunization (GAVI) to build surveillance sys-
tems to monitor trends in bacterial meningitis,34,35 we pro-
pose the use of population-based data on GAS meningitis to
estimate the burden of GAS invasive diseases and to plan
appropriate immunization strategies.
Our findings indicate that the 26-valent, M protein-based
vaccine will not be useful in preventing GAS meningitis in our
setting. Among GAS meningitis cases, 40% were <1 year of
age, an age group thatmay not be targeted for immunization.
Furthermore, only 10% of the meningitis isolates had emm
types represented in the 26-valent vaccine. It is important to
note that GAS meningitis is a rare disease and the primary
goal of the multivalent vaccine is the prevention of more
common forms of invasive disease, pharyngitis, and sequelae
such as rheumatic fever. However, the low proportion of
meningitis isolates with vaccine emm types in our study raises
the question of whether the 26-valent vaccine will provide
adequate coverage of the circulating GAS that cause invasive
disease in Brazil. The distribution of emm types in meningitismay differ from those of types that cause invasive disease in
general. Nevertheless, further research is required to deter-
mine the distribution of emm types in invasive disease, such
that recommendations can be made on the benefits that
multivalent GAS vaccines may afford in Brazil.
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